Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
adjuvant
immune checkpoint inhibitors
immunotherapy
lung cancer
neoadjuvant
non-small-cell lung carcinoma (NSCLC)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Nov 2022
25 Nov 2022
Historique:
received:
25
10
2022
revised:
17
11
2022
accepted:
17
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage non-small cell lung cancer (NSCLC) remains dismal for common relapses after curative surgery, considerable efforts are currently focused on bringing immunotherapy into neoadjuvant and adjuvant settings. Previously, perioperative chemotherapy showed only a modest but significative improvement in overall survival. The presence of broad tumor neoantigens load at primary tumor prior to surgery as well as the known immunosuppressive status following resection represent the main rationale for immunotherapy in early disease. Several trials have been conducted in recent years, leading to atezolizumab and nivolumab approval in the adjuvant and neoadjuvant setting, respectively, and perioperative immunotherapy in NSCLC remains a field of active clinical and preclinical investigation. Unanswered questions in perioperative therapy in NSCLC include the optimal sequence and timing of chemotherapy and immunotherapy, the potential of combination strategies, the role of predictive biomarkers for patient selection and the choice of useful endpoints in clinical investigation.
Identifiants
pubmed: 36497292
pii: cancers14235810
doi: 10.3390/cancers14235810
pmc: PMC9735901
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Int J Mol Sci. 2019 Apr 12;20(8):
pubmed: 31013788
J Thorac Cardiovasc Surg. 2022 Feb;163(2):427-436
pubmed: 33985811
Cancer Res. 1994 Mar 1;54(5):1286-91
pubmed: 7907000
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Immunol. 2010 Mar 1;184(5):2449-57
pubmed: 20124103
Invest New Drugs. 2012 Apr;30(2):833-45
pubmed: 21153753
Immunity. 2018 Mar 20;48(3):417-433
pubmed: 29562193
J Thorac Oncol. 2010 Apr;5(4):510-6
pubmed: 20107424
Expert Rev Anticancer Ther. 2017 Jun;17(6):555-561
pubmed: 28403675
Cancer Discov. 2016 Dec;6(12):1382-1399
pubmed: 27663893
Cancer Discov. 2017 Dec;7(12):1394-1403
pubmed: 28899864
Clin Cancer Res. 2010 Sep 15;16(18):4583-94
pubmed: 20702612
Lancet Oncol. 2019 Mar;20(3):361-370
pubmed: 30709633
J Clin Oncol. 2021 Aug 10;39(23):2574-2585
pubmed: 34236916
Lancet Oncol. 2003 Dec;4(12):760-8
pubmed: 14662433
J Immunother Cancer. 2022 Oct;10(10):
pubmed: 36270733
Ann Oncol. 2019 Feb 1;30(2):219-235
pubmed: 30608567
PLoS One. 2016 May 19;11(5):e0155947
pubmed: 27196057
J Thorac Oncol. 2009 Nov;4(11):1380-8
pubmed: 19861907
Int J Mol Sci. 2017 Aug 17;18(8):
pubmed: 28817109
Cancer Res. 2013 Jan 1;73(1):97-107
pubmed: 23090117
N Engl J Med. 2018 May 24;378(21):1976-1986
pubmed: 29658848
Science. 2020 Jan 31;367(6477):
pubmed: 32001626
Lancet Oncol. 2022 Oct;23(10):1274-1286
pubmed: 36108662
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Cochrane Database Syst Rev. 2015 Mar 02;(3):CD011430
pubmed: 25730344
J Clin Oncol. 2022 Apr 20;40(12):1301-1311
pubmed: 35108059
Lancet. 2021 Oct 9;398(10308):1344-1357
pubmed: 34555333
Oncoimmunology. 2019 Mar 1;8(5):e1581530
pubmed: 31069141
Ann Thorac Surg. 2019 Jun;107(6):1866-1875
pubmed: 30557543
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Pharmaceuticals (Basel). 2022 Mar 09;15(3):
pubmed: 35337133
J Cancer Res Clin Oncol. 1997;123(9):469-77
pubmed: 9341895
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
Lancet Oncol. 2020 Nov;21(11):1413-1422
pubmed: 32979984
Front Oncol. 2022 Apr 20;12:817548
pubmed: 35515125
Biomed Pharmacother. 2017 May;89:1235-1241
pubmed: 28320090
Nat Commun. 2021 Aug 19;12(1):5045
pubmed: 34413300
Nat Med. 2021 Mar;27(3):504-514
pubmed: 33603241
Ann Surg Oncol. 2008 Jul;15(7):2042-52
pubmed: 18398660
J Leukoc Biol. 2012 Sep;92(3):539-51
pubmed: 22654121
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32929052
J Clin Oncol. 2022 Apr 1;40(10):1127-1129
pubmed: 35167335
J Surg Res. 2015 Mar;194(1):185-93
pubmed: 25475022
Ann Oncol. 2021 Dec;32(12):1637-1642
pubmed: 34481037
Ann Surg. 2013 Jul;258(1):158-68
pubmed: 23108132
JAMA Oncol. 2021 Dec 01;7(12):1824-1832
pubmed: 34673888
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
J Clin Oncol. 2007 Oct 10;25(29):4569-74
pubmed: 17876008
Nat Med. 2022 Oct;28(10):2155-2161
pubmed: 36097216
J Immunol Res. 2014;2014:286170
pubmed: 24868562
J Immunother Cancer. 2019 Dec 4;7(1):339
pubmed: 31801611
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1209-1219
pubmed: 32043180
Oncoimmunology. 2018 Mar 1;7(6):e1431082
pubmed: 29872554
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
J Thorac Dis. 2018 Apr;10(Suppl 9):S1032-S1036
pubmed: 29850182
J Immunol. 2016 Apr 15;196(8):3460-9
pubmed: 26969754
J Clin Med. 2020 Dec 18;9(12):
pubmed: 33353113
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Eur J Clin Invest. 2000 Mar;30(3):230-8
pubmed: 10692000
J Thorac Oncol. 2020 May;15(5):816-826
pubmed: 32036071
Transl Lung Cancer Res. 2021 Jan;10(1):590-606
pubmed: 33569339
J Clin Oncol. 2008 Jul 20;26(21):3552-9
pubmed: 18506026
J Immunother Cancer. 2018 Sep 3;6(1):86
pubmed: 30176921
J Thorac Oncol. 2020 May;15(5):709-740
pubmed: 32004713
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Int J Mol Sci. 2020 Aug 31;21(17):
pubmed: 32878298
Nat Med. 2020 Apr;26(4):475-484
pubmed: 32273608
Cancer Immunol Immunother. 2015 Nov;64(11):1383-92
pubmed: 26183035
N Engl J Med. 2020 Oct 29;383(18):1711-1723
pubmed: 32955177
Transl Lung Cancer Res. 2022 Feb;11(2):277-294
pubmed: 35280319
Oncotarget. 2017 Mar 7;8(10):17050-17058
pubmed: 28178645
N Engl J Med. 2022 May 26;386(21):1973-1985
pubmed: 35403841
Surgery. 2000 Mar;127(3):329-36
pubmed: 10715990
ESMO Open. 2022 Apr;7(2):100410
pubmed: 35247871
Cell. 2022 Aug 4;185(16):2918-2935.e29
pubmed: 35803260
Lancet Oncol. 2020 Jun;21(6):786-795
pubmed: 32386568
J Clin Oncol. 2022 Sep 1;40(25):2924-2933
pubmed: 35576508
Ann Surg. 2009 May;249(5):727-34
pubmed: 19387333
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911